This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results
For the treatment of hypertension, depending on the baseline risk, the incremental cost per QALY gained with candesartan over generic losartan ranged from £41,469 to £52,644 in men and from £41,591 to £85,244 in women. These figures were above the commonly used cost-effectiveness threshold of £40,000 per QALY.
The cost-effectiveness of candesartan decreased as the baseline risk lowered, but it remained almost always above £40,000 per QALY. Candesartan became increasingly unfavourable, when the acquisition cost of generic losartan dropped, or in younger cohorts. Generic losartan could save approximately £200 million per year in drug costs for the NHS.
For heart failure, no head-to-head trials were found and an economic evaluation was not carried out.
